← All trials
NCT04317040
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 8, 2020
- Primary completion
- May 31, 2021
- Completion date
- May 31, 2022
- First posted
- Mar 20, 2020
- Last posted
- Apr 10, 2020
- Enrollment
- 230
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- OncoImmune, Inc.Lead sponsor
- University of MarylandOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.